This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-Deruxtecan Related ILD - A Real-World Experience

731 views
October 14, 2024
Comments 0
Login to view comments. Click here to Login